Lizzy Liu presented “Risk in preferences for breast cancer genomic risk screening and subsequent prevention protocols.”

Last week, Lizzy Liu and Mackenzie Bourke presented in an organised session at the AHES Conference in Canberra on the value of population-wide genomic risk assessment for cancer screening, alongside A/Prof Julia Steinberg from the Daffodil Centre.

Recently our team conducted two #DCEs as part of the BabyScreen+ program to elicit the Australian public’s preferences, values, and priorities for genomic newborn screening (gNBS) and its implementation.

Read more here: sciencedirect.com/science/arti...

Excited to welcome Thuy Dung (“Dzung”) Nguyen as our new Research Assistant in the Economics of Genomics and Precision Medicine Unit! Dzung will be contributing to a project evaluating the cost-effectiveness of genomic testing for children/adults with suspected kidney disease.

This systematic review highlights where genomic medicine is likely cost-effective across the cancer care continuum, from:
🔹 Prevention & early detection
🔹 Diagnosis, staging & planning
🔹 Treatment
🔹 Managing refractory/relapsed disease
🔹 Palliative & end-of-life care

Preferences like testing uptake, treatment adherence, and trust in the healthcare system are key to evaluating genomic medicine. Ignoring them can bias cost-effectiveness and policy relevance.

🔎 Read the paper our team supported: rdcu.be/eaJBy

Using #MCDA, we elicited expert preference values for the diagnostic, clinical, family, economic, and societal components of genomic utility. This enabled the development of a scoring system ranging from 0% to 100%. The utility indicators used in the scale are shown in the table.

Cancer Australia recently launched the National Framework for Genomics in Cancer Control, a major step toward integrating genomics into routine cancer care for all Australians.

Read the Framework: canceraustralia.gov.au/key-initiati...

Our recent micro-costing paper found that proteomics offers a more cost-effective solution with broader applications compared to respiratory chain enzymology for mitochondrial disorders in Australia. Read more of our findings here: ojrd.biomedcentral.com/articles/10....